The U.S. Department of Health and Human Services (HHS), recently awarded Phlow Corp. the Office of Small and Disadvantaged Business Utilization (OSDBU), Small Business Prime Contractor of the Year Award. Phlow Corp. is a U.S.-based, public benefit corporation committed to solving America’s broken essential medicine supply chain. This award recognizes Phlow for its performance during the previous fiscal year on its contract with HHS.
“We are honored to receive this recognition from HHS as we work together to reliably supply affordable, high-quality, essential medicines through U.S.-based advanced manufacturing processes,” said Eric Edwards, M.D., Ph.D., co-founder, President, and CEO of Phlow. “We are thrilled to continue expanding our existing relationship with the U.S. Government to create a resilient and sustainable essential medicines supply chain that will benefit all Americans.”
Phlow’s vision is to make the U.S. a country where every human being has access to the essential medicines necessary to sustain life and conquer disease. Throughout 2020 and 2021, Phlow has worked toward strengthening the U.S. essential medicines supply chain by offering a novel, resilient, end-to-end solution that is U.S.-based, comprehensive, and fully integrated.
The U.S. Government and Phlow recognize the importance of enhancing domestic manufacturing as well as providing diversity in the essential medicine supply chain by leveraging private sector partnerships to achieve essential medicine supply chain resilience. With contract funding support from the Biomedical Advanced Research and Development Authority (BARDA), part of the office of Assistant Secretary for Preparedness and Response (ASPR) at HHS, Phlow is currently developing a comprehensive advanced development and manufacturing infrastructure, including a Strategic Active Pharmaceutical Ingredient Reserve (“SAPIR”), intended to help ensure the U.S. has an uninterrupted supply of affordable essential life-saving medicine ingredients that can be rapidly converted to finished essential medicines to meet increasing demands due to supply chain disruptions whether from trade challenges, international conflicts, natural disasters, or future public health emergencies.